We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 15, 2020

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival in Patients With HR+, ERBB2− Metastatic Breast Cancer

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
JAMA Oncol 2020 Sep 03;[EPub Ahead of Print], SM Tolaney, R Barroso-Sousa, T Keenan, T Li, L Trippa, I Vaz-Luis, G Wulf, L Spring, NF Sinclair, C Andrews, J Pittenger, ET Richardson, D Dillon, NU Lin, B Overmoyer, AH Partridge, E Van Allen, EA Mittendorf, EP Winer, IE Krop

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading